共 79 条
[1]
Hu JCC(2006)A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin Cancer Res Off J Am Assoc Cancer Res 12 6737-6747
[2]
Coffin RS(2017)Review: oncolytic virotherapy, updates and future directions Oncotarget 8 102617-102639
[3]
Davis CJ(2017)Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma Am J Clin Dermatol 18 1-15
[4]
Fountzilas C(2017)Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: a report of 2 cases JAAD Case Rep 3 185-189
[5]
Patel S(2016)Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study J Immunother Cancer 4 12-2788
[6]
Mahalingam D(2015)Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol Off J Am Soc Clin Oncol 33 2780-7093
[7]
Bommareddy PK(2016)Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the phase III OPTiM trial OncoTargets Ther 9 7081-1119.e10
[8]
Patel A(2019)Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma J Immunother Cancer 7 145-3965
[9]
Hossain S(2017)Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy Cell 170 1109-4641
[10]
Kaufman HL(2017)Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma J Clin Oncol Off J Am Soc Clin Oncol 6 36-564